Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleA pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men
Author(s)Riggs PK, Vaida F, Rossi SS, Sorkin LS, Gouaux B, Grant I, Ellis RJ
Journal, Volume, IssueBrain Res. 2012 Jan 11;1431:46-52
Major outcome(s)Cannabis administration was associated with significant increases in plasma levels of ghrelin and leptin, and decreases in PYY, but did not significantly influence insulin levels
IndicationAppetite loss/weight loss;HIV/AIDSAbstract
MedicationCannabis

RATIONALE:
The endocannabinoid system is under active investigation as a pharmacological target for obesity management due to its role in appetite regulation and metabolism. Exogenous cannabinoids such as tetrahydrocannabinol (THC) stimulate appetite and food intake. However, there are no controlled observations directly linking THC to changes of most of the appetite hormones.

OBJECTIVES:
We took the opportunity afforded by a placebo-controlled trial of smoked medicinal cannabis for HIV-associated neuropathic pain to evaluate the effects of THC on the appetite hormones ghrelin, leptin and PYY, as well as on insulin.

METHODS:
In this double-blind cross-over study, each subject was exposed to both active cannabis (THC) and placebo.

RESULTS:
Compared to placebo, cannabis administration was associated with significant increases in plasma levels of ghrelin and leptin, and decreases in PYY, but did not significantly influence insulin levels.

CONCLUSION:
These findings are consistent with modulation of appetite hormones mediated through endogenous cannabinoid receptors, independent of glucose metabolism.

Copyright © 2011 Elsevier B.V. All rights reserved

Route(s)Inhalation
Dose(s)
Duration (days)
Participants7 out of 28 patients with HIV-associated neuropathic pain
DesignControlled study
Type of publicationMedical journal
Address of author(s)Center for Medicinal Cannabis Research (CMCR) and HIV Neurobehavioral Research Center (HNRC), University of California, San Diego, USA. roellis@ucsd.edu
Full texthttp://www.sciencedirect.com/science/article/pii/S0006899311020282

[Back to Overview]  [IACM Homepage]


up